Nautilus Biotechnology Q3 2026 Results: Net Loss of $15.6M, Loss Widens
Nautilus Biotechnology reported total revenue of $424,000 for the nine months ended September 30, 2026, primarily from grant and service revenue, compared to zero revenue in the prior year. The company's total assets decreased from $191.1 million at the end of 2025 to $148.9 million as of September 30, 2026, driven by an accumulated deficit of $376.8 million.
- Key figure
- Net loss $15.6M